Glecirasib in KRAS

• Tác giả: Guangyu An, Yi Ba, Chunmei Bai, Xueqin Chen, Ying Cheng, Zhaoxia Dai, Yuli Ding, Jian Fang, Yanhong Gu, Changlu Hu, Weiguo Hu, Yanping Hu, Bo Jin, Qiao Li, Qingshan Li, Xingya Li, Yongsheng Li, Zhihua Li, Lian Liu, Zhe Liu, Zhihua Liu, Dongqing Lv, Rui Ma, Zhiyue Rao, Yanhong Shang, Yuankai Shi, Zhengbo Song, Kejing Tang, Mengzhao Wang, Yinxiang Wang, Yongsheng Wang, Zhen Wang, Andrea Wang-Gillam, Lin Wu, Guohao Xia, Ligang Xing, Puyuan Xing, Jianping Xiong, Runxiang Yang, Yu Yao, Qitao Yu, Yan Yu, Jian Zhang, Enfeng Zhao, Hui Zhao, Jun Zhao, Yanqiu Zhao, Jin Zhou, Wu Zhuang
• Ngôn ngữ: eng
• Ký hiệu phân loại: 152.1 Sensory perception
• Thông tin xuất bản: United States : Nature medicine , 2025
• Bộ sưu tập: NCBI
• ID: 720792

Tóm tắt

Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRAS